scholarly journals DNA Repair Response Modulation Potentiates Low Dose Cisplatin Effects in HeLa Cells

Oncomedicine ◽  
2018 ◽  
Vol 3 ◽  
pp. 59-66
Author(s):  
Aayushi Jain ◽  
Devashree Jahagirdar ◽  
Nilesh Kumar Sharma
Keyword(s):  
Dna Repair ◽  
Hela Cells ◽  
Low Dose ◽  
Response Modulation

Interferon β improves the efficacy of low dose cisplatin by inhibiting NF-κB/p-Akt signaling on HeLa cells

2016 ◽  
Vol 82 ◽  
pp. 124-132 ◽  
Author(s):  
Purushoth Ethiraj ◽  
Karpagam Veerappan ◽  
Shila Samuel ◽  
Sundaresan Sivapatham
Keyword(s):  
Hela Cells ◽  
Low Dose ◽  
Akt Signaling ◽  
Interferon Β

DNA Repair of Clustered Uracils in HeLa Cells

2005 ◽  
Vol 345 (4) ◽  
pp. 731-743 ◽  
Author(s):  
Svitlana Malyarchuk ◽  
Lynn Harrison
Keyword(s):  
Dna Repair ◽  
Hela Cells

scholarly journals Low-dose hyper-radiosensitivity of progressive and regressive cells isolated from a rat colon tumour: Impact of DNA repair

2008 ◽  
Vol 84 (7) ◽  
pp. 533-548 ◽  
Author(s):  
Charles Thomas ◽  
Josiane Charrier ◽  
Catherine Massart ◽  
Michel Cherel ◽  
Bernard Fertil ◽  
...  
Keyword(s):  
Dna Repair ◽  
Low Dose ◽  
Rat Colon ◽  
Colon Tumour

Bortezomib Enhances Melphalan Response by Altering Fanconi Anemia (FA)/BRCA Pathway Expression and Function.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 840-840 ◽  
Author(s):  
Danielle N. Yarde ◽  
Lori A. Hazlehurst ◽  
Vasco A. Oliveira ◽  
Qing Chen ◽  
William S. Dalton
Keyword(s):  
Gene Expression ◽  
Dna Damage ◽  
Dna Repair ◽  
Low Dose ◽  
Dna Damage Repair ◽  
Myeloma Cell ◽  
Myeloma Cells ◽  
Multiple Myeloma Cell ◽  
Damage Repair ◽  
Pre Treatment

Abstract The FA/BRCA pathway is involved in DNA damage repair and its importance in oncogenesis has only recently been implicated. Briefly, 8 FA/BRCA pathway family members facilitate the monoubiquitination of FANCD2. Upon monoubiquitination, FANCD2 translocates to the DNA repair foci where it interacts with other proteins to initiate DNA repair. Previously, we reported that the FA/BRCA pathway is upregulated in multiple myeloma cell lines selected for resistance to melphalan (Chen, et al, Blood 2005). Further, reducing FANCF in the melphalan resistant 8226/LR5 myeloma cell line partially reversed resistance, whereas overexpressing FANCF in the drug sensitive 8226/S myeloma line conferred resistance to melphalan. Others have reported, and we have also verified, that bortezomib enhances melphalan response in myeloma cells; however, the mechanism of enhanced melphalan activity in combination with bortezomib has not been reported. Based on our observation that the FA/BRCA pathway confers melphalan resistance, we hypothesized that bortezomib enhances melphalan response by targeting FA/BRCA DNA damage repair pathway genes. To investigate this hypothesis, we first analyzed FA/BRCA gene expression in 8226/S and 8226/LR5 cells treated with bortezomib, using a customized microfluidic card (to detect BRCA1, BRCA2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, RAD51 and RAD51C) and q-PCR. Interestingly, we found that low dose (5nM) bortezomib decreased many FA/BRCA pathway genes as early as 2 hours, with maximal decreases seen at 24 hours. Specifically, 1.5- to 2.5-fold decreases in FANCA, FANCC, FANCD2, FANCE and RAD51C were seen 24 hours post bortezomib exposure. Moreover, pre-treatment of myeloma cells with low dose bortezomib followed by melphalan treatment revealed a greater than 2-fold reduction in FANCD2 gene expression levels. We also found that melphalan treatment alone enhanced FANCD2 protein expression and activation (monoubiquitination), whereas the combination treatment of bortezomib followed by melphalan decreased activation and overall expression of FANCD2 protein. Taken together, these results suggest that bortezomib enhances melphalan response in myeloma by targeting the FA/BRCA pathway. Further understanding of the role of the FA/BRCA pathway in determining melphalan response may allow for more customized and effective treatment of myeloma.

Dry mass and average phase shift dynamics in HeLa cells subjected to low-dose photodynamic treatment

2018 ◽  
Author(s):  
Andrey V. Belashov ◽  
Anna A. Zhikhoreva ◽  
Tatiana Belyaeva ◽  
Elena Kornilova ◽  
Anna Salova ◽  
...  
Keyword(s):  
Phase Shift ◽  
Hela Cells ◽  
Low Dose ◽  
Dry Mass ◽  
Photodynamic Treatment ◽  
Shift Dynamics
Sign in / Sign up

Export Citation Format

Share Document